Speaker

Professor Tony Mok, BBS, BMSc, MD, FRCP(C), FRCP(Edin), FRCP(Lond), FHKCP, FHKAM(Medicine), FASCO, Member of ASHK, The Chinese University of Hong Kong, Hong Kong SAR, China

Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto.  After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer.  He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international phase III studies including the FASTACT 2, PROFILE 1014, IMPRESS, ARCHER 1050, ALEX, AURA 3 and KEYNOTE 042.  These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice.  He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on oncogene driven lung cancer and immunotherapy.  His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO.  He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.

Professor Mok has contributed to over 315 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks.  He served as an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals.  He is the Past President, Past Treasurer of the International Association for the Study of Lung Cancer (IASLC) and Past Board of Director for ASCO.  He is a member of the Board of Directors for AstraZeneca, Aurora Tele-Oncology, HutchMed (China), Insighta, St. Stephen’s College & Preparatory School Council and Hong Kong Academy of Sciences (ASHK).  He is active in international education activity and has made significant contributions to AACR, ASCO, CSCO and ESMO.  His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul 2020, Jr Scientific Award in 2017, National Science and Technology Progress Award in 2017, CSCO Annual Achievement Award in 2017, ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care 2020, SingTao Hong Kong Leader of the Year 2020 Award and The Sixth Fok Ying-Tung Prize The World Outstanding Chinese Doctor Award in 2023.  His article in the New England Journal of Medicine has been selected as one of the most “Notable Articles in 2017”.  He is one of the “Highly Cited Researchers” by Clarivate Analytics for five consecutive years from 2018 to 2023.  He was awa rded with the Bronze Bauhinia Star (BBS) by the Government of Hong Kong Special Administrative Region in 2022 to recognize his dedicated service in public affairs.